Vismodegib: A Review in Advanced Basal Cell Carcinoma

Overview of attention for article published in Drugs, July 2018

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (63rd percentile)
Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 5 X users

Citations

dimensions_citation: 65 Dimensions

Readers on

mendeley: 87 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 5 X posts from 5 X users, with an upper bound of 1,895 followers.

RT @NMacagnoMD: 4/4 Secondary resistance (SMO mutations) occurs in up to 40% of locally advanced BCC, but is extremely rare in metastatic B…

21 Mar 2021

Reply Repost Favourite

RT @NMacagnoMD: 4/4 Secondary resistance (SMO mutations) occurs in up to 40% of locally advanced BCC, but is extremely rare in metastatic B…

21 Mar 2021

Reply Repost Favourite

4/4 Secondary resistance (SMO mutations) occurs in up to 40% of locally advanced BCC, but is extremely rare in metastatic BCC so far… 📚 https://t.co/fneIC3Gzj0 📚 https://t.co/IhfU9pCDvE

20 Mar 2021

Reply Repost Favourite

RT @TargetOncology: Our latest @AdisJournals Drug Evaluation on #Vismodegib in Advanced Basal Cell Carcinoma https://t.co/OSh8tNfKIA

23 Jul 2018

Reply Repost Favourite

Our latest @AdisJournals Drug Evaluation on #Vismodegib in Advanced Basal Cell Carcinoma https://t.co/OSh8tNfKIA

23 Jul 2018

Reply Repost Favourite